Joint Formulary & PAD

Ospemifene - Vaginal atrophy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
BNF SPC
R
Restrictions / Comments :
Important
Initiation in primary care following specialist recommendation. Reserve for severe dryness or when other treatments are ineffective / contraindicated.

PAD Profile

ChemicalSubstance :
Ospemifene
Indication :
Vaginal atrophy
Group Name :
Keywords :
menopause, menopausal symptoms, vaginal oestrogen, oestrogen deficiency, vaginal dryness, selective oestrogen receptor modulators
Brand Names Include :
Senshio
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Ospemifene is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Vaginal atrophy.

Committee Recommendations (1)

The Surrey Heartlands APC has agreed a traffic light status and place in therapy for the treatments of menopausal disorders in line with the CKS recommenations:

Menopause | Health topics A to Z | CKS | NICE